Diminished transforming growth factor β2 production leads to increased expression of a profibrotic procollagen α2 type I messenger RNA variant in embryonic fibroblasts of UCD-200 chickens, a model for systemic sclerosis

Arthritis and Rheumatism

Volumn 52, Issue 6, 2005, Pages 1804-1811

  Prelog, Martina ^a   Scheidegger, Paul ^b   Peter, Silvia ^a   Gershwin, M Eric ^c   Wick, Georg ^a   Sgonc, Roswitha ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN GEL; CYTOKINE; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CHICKEN; CONTROLLED STUDY; CYTOKINE PRODUCTION; EMBRYO; EMBRYO CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; FIBROSIS; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC VARIABILITY; NONHUMAN; PRIORITY JOURNAL; PROCOLLAGEN ALPHA2 TYPE 1 GENE; PROCOLLAGEN GENE; RIBONUCLEASE PROTECTION ASSAY; SCLERODERMA; STRAIN DIFFERENCE; SUPERNATANT; SYSTEMIC SCLEROSIS;

ANIMALS; CELLS, CULTURED; CHICK EMBRYO; COLLAGEN TYPE I; FIBROBLASTS; MODELS, ANIMAL; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

EID: 20744455828     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21109     Document Type: Article

References (43)

1. White B. Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 1996;22:695-708.
2. Derk CT, Jimenez SA. Systemic sclerosis: current views of its pathogenesis. Autoimmun Rev 2003;2:181-91.
3. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996;98:785-92.
4. Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000;43:2550-62.
5. Kissin EY, Korn JH. Fibrosis in scleroderma. Rheum Dis Clin North Am 2003;29:351-69.
6. Taipale J, Miyazono K, Heldin CH, Keski-Oja J. Latent transforming growth factor-β1 associates to fibroblast extracellular matrix via latent TGF-β binding protein. J Cell Biol 1994;124:171-81.
7. Denton CP, Abraham DJ. Transforming growth factor-β and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001;13:505-11.
8. Varga J. Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis [review]. Arthritis Rheum 2002; 46:1703-13.
9. Pannu J, Gore-Hyer E, Yamanaka M, Smith EA, Rubinchik S, Dong JY, et al. An increased transforming growth factor β receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor β receptor type II in scleroderma. Arthritis Rheum 2004;50:1566-77.
10. Cotton SA, Herrick AL, Jayson MI, Freemont AJ. TGF β: a role in systemic sclerosis? J Pathol 1998;184:4-6.
11. Kikuchi K, Hartl CW, Smith EA, LeRoy EC, Trojanowska M. Direct demonstration of transcriptional activation of collagen gene expression in systemic sclerosis fibroblasts: insensitivity to TGF β1 stimulation. Biochem Biophys Res Commun 1992;187:45-50.
12. McWhirter A, Colosetti P, Rubin K, Miyazono K, Black C. Collagen type I is not under autocrine control by transforming growth factor-β1 in normal and scleroderma fibroblasts. Lab Invest 1994;71:885-94.
13. Gruschwitz M, Muller PU, Sepp N, Hofer E, Fontana A, Wick G. Transcription and expression of transforming growth factor type β in the skin of progressive systemic sclerosis: a mediator of fibrosis? J Invest Dermatol 1990;94:197-203.
14. Falanga V, Gerhardt CO, Dasch JR, Takehara K, Ksander GA. Skin distribution and differential expression of transforming growth factor β1 and β2. J Dermatol Sci 1992;3:131-6.
15. Gabrielli A, di Loreto C, Taborro R, Candela M, Sambo P, Nitti C, et al. Immunohistochemical localization of intracellular and extracellular associated TGβ3 in the skin of patients with systemic sclerosis (scleroderma) and primary Raynaud's phenomenon. Clin Immunol Immunopathol 1993;68:340-9.
16. Querfeld C, Eckes B, Huerkamp C, Krieg T, Sollberg S. Expression of TGF-βl, -β2 and -β3 in localized and systemic scleroderma. J Dermatol Sci 1999;21:13-22.
17. Jimenez SA, Christner PJ. Murine animal models of systemic sclerosis. Curr Opin Rheumatol 2002;14:671-80.
18. Gershwin ME, Abplanalp H, Castles JJ, Ikeda RM, van der Water J, Eklund J, et al. Characterization of a spontaneous disease of white leghorn chickens resembling progressive systemic sclerosis (scleroderma). J Exp Med 1981;153:1640-59.
19. Sgonc R, Dietrich H, Sicherer C, Wick G, Christner PJ, Jimenez SA. Lack of endothelial cell apoptosis in the dermis of tight skin 1 and tight skin 2 mice. Arthritis Rheum 1999;42:581-4.
20. Sgonc R. The vascular perspective of systemic sclerosis: of chickens, mice and men. Int Arch Allergy Immunol 1999;120:169-76.
21. Haynes DC, Gershwin ME. Diversity of autoantibodies in avian scleroderma: an inherited fibrotic disease of white leghorn chickens. J Clin Invest 1984;73:1557-68.
22. Ausserlechner MJ, Sgonc R, Dietrich H, Wick G. Altered procollagen mRNA expression during the progression of avian scleroderma. Mol Med 1997;3:654-62.
23. Hu Y, Dietrich H, Herold M, Heinrich PC, Wick G. Disturbed immuno-endocrine communication via the hypothalamo-pituitary-adrenal axis in autoimmune disease. Int Arch Allergy Immunol 1993;102:232-41.
24. Brezinschek HP, Gruschwitz M, Sgonc R, Moormann S, Herold M, Gershwin ME, et al. Effects of cytokine application on glucocorticoid secretion in an animal model for systemic scleroderma. J Autoimmun 1993;6:719-33.
25. Weining KC, Schultz U, Munster U, Kaspers B, Staeheli P. Biological properties of recombinant chicken interferon-γ. Eur J Immunol 1996;26:2440-7.
26. Dietrich HM, Oliveira-dos-Santos AJ, Hala K, Wick G. Skin allograft survival in chicken strains with spontaneous autoimmune diseases. Poult Sci 1996;75:285-93.
27. Ausserlechner MJ, Sgonc R, Wick G. Chemiluminescence-based RNase protection assays for simultaneous quantification of procollagen mRNAs containing AU-rich regions. Biotechniques 1998; 24:366-70.
28. Trojanowska M, LeRoy EC, Eckes B, Krieg T. Pathogenesis of fibrosis: type 1 collagen and the skin. J Mol Med 1998;76:266-74.
29. Ghosh AK. Factors involved in the regulation of type I collagen gene expression: implication in fibrosis. Exp Biol Med 2002;227: 301-14.
30. Needleman BW, Choi J, Burrows-Mezu A, Fontana JA. Secretion and binding of transforming growth factor β by scleroderma and normal dermal fibroblasts. Arthritis Rheum 1990;33:650-6.
31. Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor β receptors. Arthritis Rheum 2001;44:474-80.
32. Sfikakis PP, McCune BK, Tsokos M, Aroni K, Vayiopoulos G, Tsokos GC. Immunohistological demonstration of transforming growth factor-β isoforms in the skin of patients with systemic sclerosis. Clin Immunol Immunopathol 1993;69:199-204.
33. Helman S, Cotton SA, Jayson MI, Hoyland J, Herrick A, Freemont AJ. Microvascular abnormality and TGF-β in systemic sclerosis skin [abstract]. Br J Rheumatol 1997;36:30.
34. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 2003;100:12319-24.
35. Shah M, Foreman DM, Ferguson MW. Neutralisation of TGF-β1 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995;108:985-1002.
36. Kahari VM, Heino J, Vuorio E. Interleukin-1 increases collagen production and mRNA levels in cultured skin fibroblasts. Biochim Biophys Acta 1987;929:142-7.
37. Abraham DJ, Shiwen X, Black CM, Sa S, Xu Y, Leask A. Tumor necrosis factor α suppresses the induction of connective tissue growth factor by transforming growth factor-β in normal and scleroderma fibroblasts. J Biol Chem 2000;275:15220-5.
38. Kessler-Becker D, Krieg T, Eckes B. Expression of pro-inflammatory markers by human dermal fibroblasts in a three-dimensional culture model is mediated by an autocrine interleukin-1 loop. Biochem J 2004;379:351-8.
39. Kahari VM, Heino J, Vuorio T, Vuorio E. Interferon-α and interferon-γ reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture. Biochim Biophys Acta 1988;968:45-50.
40. Gillery P, Serpier H, Polette M, Bellon G, Clavel C, Wegrowski Y, et al. γ-interferon inhibits extracellular matrix synthesis and remodeling in collagen lattice cultures of normal and scleroderma skin fibroblasts. Eur J Cell Biol 1992;57:244-53.
41. Ghosh AK, Yuan W, Mori Y, Chen S, Varga J. Antagonistic regulation of type I collagen gene expression by interferon-γ and transforming growth factor-β: integration at the level of p300/CBP transcriptional coactivators. J Biol Chem 2001;276:11041-8.
42. Bell E, Ivarsson B, Merrill C. Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc Natl Acad Sci U S A 1979;76: 1274-8.
43. Eckes B, Zigrino P, Kessler D, Holtkotter O, Shephard P, Mauch C, et al. Fibroblast-matrix interactions in wound healing and fibrosis. Matrix Biol 2000;19:325-32.